title: Further investigations into the potentiation of infection by intra-articular injection of polysulfated glycosaminoglycan and the effect of filtration and intra-articular injection of amikacin.
abstract: Polysulfated glycosaminoglycan (PSGAG) recently have been reported to potentiate the infectivity of Staphylococcus aureus in horses with experimentally induced septic arthritis. Four groups of 8 horses each had 1 midcarpal joint injected with approximately 33 viable colony-forming units (CFU) of S aureus plus either 1 ml of saline solution (group 1), 250 mg of PSGAG (group 2), 250 mg of PSGAG passed through a 0.6-microns filter (group 3), or 250 mg of PSGAG plus 125 mg of amikacin (group 4). Horses that developed clinical signs consistent with sepsis were euthanatized, and samples were collected at necropsy. Horses that survived had samples obtained by use of arthroscopy at days 13 and 14 after injection. Staphylococcus aureus was isolated from 1 group-1 horse, 8 group-2 horses, and 7 of 7 group-3 horses that met protocol, but was not isolated from any group-4 horses. All 16 aforementioned horses had clinical signs, results of synovial fluid analysis, and gross pathologic and synovial membrane histopathologic findings that were consistent with septic arthritis. Polysulfated glycosaminoglycan (250 mg) increased the infectivity of 33 CFU of S aureus (P = 0.001); filtering the PSGAG had no effect. Intra-articular injection of 125 mg of amikacin immediately after inoculating the joint with 33 CFU of S aureus significantly (P = 0.001) decreased potentiation of infection by the PSGAG.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523.
authors.forename: S B
authors.initials: SB
authors.lastname: Gustafson
authors.forename: C W
authors.initials: CW
authors.lastname: McIlwraith
authors.forename: R L
authors.initials: RL
authors.lastname: Jones
authors.forename: H E
authors.initials: HE
authors.lastname: Dixon-White
mesh_terms: D000583:Amikacin / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D006025:Glycosaminoglycans / Q000008:administration & dosage / Q000494:pharmacology*; D006734:Horse Diseases / Q000382:microbiology*; D006736:Horses / Q000382:microbiology; D007270:Injections, Intra-Articular; D007592:Joint Diseases / Q000382:microbiology / Q000662:veterinary*; D013203:Staphylococcal Infections / Q000382:microbiology / Q000662:veterinary*; D013211:Staphylococcus aureus / Q000472:pathogenicity; D013582:Synovial Fluid / Q000032:analysis; D013585:Synovitis / Q000382:microbiology / Q000662:veterinary
chemical_list: D006025:Glycosaminoglycans; D000583:Amikacin